Kane Biotech Inc. (CVE:KNE – Get Free Report)’s share price traded down 12.5% during mid-day trading on Monday . The company traded as low as C$0.07 and last traded at C$0.07. 136,000 shares changed hands during mid-day trading, an increase of 174% from the average session volume of 49,628 shares. The stock had previously closed at C$0.08.
Kane Biotech Stock Down 6.3%
The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39. The business’s 50 day moving average is C$0.09 and its 200-day moving average is C$0.10. The company has a market cap of C$10.80 million, a PE ratio of 1.88 and a beta of 0.52.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Recommended Stories
- Five stocks we like better than Kane Biotech
- Are Penny Stocks a Good Fit for Your Portfolio?
- Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
- Energy and Oil Stocks Explained
- 4 Automaker Stocks React to Tariffs: Winners and Losers
- What Are the U.K. Market Holidays? How to Invest and Trade
- Here’s Why Call Option Traders Love Dutch Bros Stock
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
